Intellia Therapeutics. has been granted a patent for a genome editing system designed for immuno-oncology applications. The patent includes a specific gRNA molecule targeting the B2M gene, featuring a complementary sequence of at least 19 nucleotides from designated SEQ IDs. GlobalData’s report on Intellia Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Intellia Therapeutics, CRISPR genome editing was a key innovation area identified from patents. Intellia Therapeutics's grant share as of June 2024 was 6%. Grant share is based on the ratio of number of grants to total number of patents.
Genome editing for immuno-oncology targeting b2m sequences
The granted patent US12037583B2 outlines a series of claims related to a guide RNA (gRNA) molecule designed for targeted genetic modification, particularly focusing on the B2M gene. The gRNA molecule consists of a trans-activating CRISPR RNA (tracr) and a CRISPR RNA (crRNA), with the crRNA containing a targeting domain that is complementary to a specific sequence of B2M. The targeting domain must include at least 19 consecutive nucleotides from designated sequences (SEQ ID NO: 5498, 5496, 5499, or 5509). The patent further details various configurations of the gRNA, including those with specific nucleic acid modifications, and the potential for the gRNA to be encoded in a nucleic acid vector, which can be a variety of viral or plasmid types.
Additionally, the patent encompasses compositions that combine the gRNA with a Cas9 molecule, which is essential for the CRISPR gene-editing process. These compositions may also include multiple gRNA molecules targeting different sequences, enhancing the versatility of the gene-editing approach. The claims extend to methods for altering target sequences in cells, particularly immune effector cells, and include the introduction of chimeric antigen receptors (CARs) for immunotherapy applications. The patent emphasizes the potential for these gRNA molecules and compositions to be utilized in therapeutic contexts, particularly in modifying immune cells to improve their efficacy against various diseases, including cancer.
To know more about GlobalData’s detailed insights on Intellia Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
